Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fimaporfin + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- PCI Biotech
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous, Local Illumination (for Fimaporfin)
01
Overview
Fimaporfin + gemcitabine + cisplatin is an experimental combination regimen under investigation primarily for advanced or unresectable biliary tract cancers, including cholangiocarcinoma. Fimaporfin is a photosensitizer used in photochemical internalization (PCI); it facilitates the release of co-administered chemotherapeutic agents from endosomes into the cytosol when activated by light. When combined with gemcitabine (an antimetabolite that inhibits DNA synthesis) and cisplatin (a platinum-based DNA cross-linker), the regimen aims to enhance the cytotoxic effects of chemotherapy within malignant cells. The combination is typically tested where locoregional disease control is needed and standard therapy is insufficient. The developer of fimaporfin is PCI Biotech; gemcitabine and cisplatin are generic agents produced by multiple companies.
- Brand names
- GemzarPlatinol
- Other names
- GCGemCis
02
Targets
RRM1DNA
Beyond the preview
Go deeper on fimaporfin + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fimaporfin + gemcitabine + cisplatin.